Xaira - About the company
Xaira is a series D company based in San Francisco (United States), founded in 2023 by Robert Nelsen, Hetu K, Marc Tessier Lavigne, David Baker and Vik Bajaj. It operates as an AI-enabled platform for drug discovery and development. Xaira has raised $1B in funding from Arch Venture Partners and Foresite Labs, with a current valuation of $4B. The company has 146 active competitors, including 64 funded and 10 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, XtalPi and Schrodinger.
Sectors and market segments that Xaira operate in
Xaira serves in the HealthTech, Life Sciences market segments.The primary business model of Xaira are:Company Details
AI-enabled platform for drug discovery and development. It combine robust product development, biological and clinical data generation, and AI methods research, both translational and fundamental for drug discovery and development process.
- Website
- www.xaira.com/
- Email ID
- *****@xaira.com
Key Metrics
Founded Year
2023
Location
San Francisco, United States
Stage
Series D
Total Funding
$1B in 1 round
Latest Funding Round
Post Money Valuation
$4B as on Apr 23, 2024
Investors
Ranked
6th among 146 active competitors
Employee Count
197 as on Mar 31, 2026
Similar Companies
Sign up to download Xaira's company profile
Xaira's funding and investors
Xaira has raised a total funding of $1B over 1 round. Its latest funding round was a Series D round on Apr 23, 2024 for $1B. 13 investors participated in its latest round. Xaira has 13 institutional investors.
Here is the list of recent funding rounds of Xaira:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 23, 2024 | $1B | Series D | $4B | - |
Access funding benchmarks and valuations. Sign up today!View details of Xaira's funding rounds and investors
Xaira's founders and board of directors
Founder? Claim ProfileThe founders of Xaira are Robert Nelsen, Hetu K, Marc Tessier Lavigne, David Baker and Vik Bajaj. Marc Tessier Lavigne is the CEO of Xaira.
Here are the details of Xaira's key team members:
- Robert Nelsen: Co-Founder & Director of Xaira.
- Hetu K: Co-Founder & CTO of Xaira. Contact Info: 1 email address
- Marc Tessier Lavigne: Co-Founder & CEO of Xaira.
- David Baker: Co-Founder of Xaira.
- Vik Bajaj: Co-Founder of Xaira. Contact Info: 1 email address
View details of Xaira's Founder profiles and Board Members
Xaira's employee count trend
Xaira has 197 employees as of Mar 26. Here is Xaira's employee count trend over the years:
Uncover Xaira's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Xaira's Competitors and alternates
Top competitors of Xaira include Recursion Pharmaceuticals, XtalPi and Schrodinger. Here is the list of Top 10 competitors of Xaira, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
2nd |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
3rd |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 66/100 | |
4th |  Healx 2014, Cambridge (United Kingdom), Series C | AI-powered drug discovery platform to treat rare diseases | $115M | 64/100 | |
5th |  METiS Therapeutics 2017, Cambridge (United States), Series B | Provider of an AI-assisted platform for drug discovery and development | $252M | 63/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 62/100 | |
8th | Provider of an AI and quantum physics to discover therapeutic molecules | $103M | 62/100 | ||
9th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
10th |  Isomorphic Labs 2021, London (United Kingdom), Series D | AI-driven platform to accelerate drug discovery process | $600M | 62/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Xaira's competitors? Click here to see the top ones
Xaira's Investments and acquisitions
Xaira has made no investments or acquisitions yet.
News related to Xaira
Filter this listMedia has covered Xaira for a total of 5 events in the last 1 year, 3 of them have been about company updates and 2 about people movement.
•
•
Xaira Therapeutics Releases First AI Model, Tests Scaling Laws in Virtual CellsEndpoints•Mar 18, 2026•Xaira
•
•
•
•
Xaira Therapeutics Appoints Bo Wang as SVP and Head of Biomedical AIBusiness Wire•Apr 03, 2025•Xaira
•
Xaira Therapeutics to expand into 73,075 square feet of space in San Francisco California.intelligence360•Jan 07, 2025•Xaira
•
Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, RegeneronEndPoints News•Dec 13, 2024•Xaira
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Xaira
Explore our recently published companies
- Alpspure Lifesciences - Delhi based, 2015 founded, Unfunded company
- Beluga - San Francisco based, 2024 founded, Unfunded company
- GOBBi - San Francisco based, 2025 founded, Unfunded company
- Galen AI - Mountain View based, 2025 founded, Unfunded company
- Styrax - Halifax based, 2021 founded, Unfunded company
- Katana Consulting - San Francisco based, 2004 founded, Unfunded company
